» Articles » PMID: 18581418

Influence of Iron Chelation on R1 and R2 Calibration Curves in Gerbil Liver and Heart

Overview
Journal Magn Reson Med
Publisher Wiley
Specialty Radiology
Date 2008 Jun 27
PMID 18581418
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

MRI is gaining increasing importance for the noninvasive quantification of organ iron burden. Since transverse relaxation rates depend on iron distribution as well as iron concentration, physiologic and pharmacologic processes that alter iron distribution could change MRI calibration curves. This article compares the effect of three iron chelators, deferoxamine, deferiprone, and deferasirox, on R1 and R2 calibration curves according to two iron loading and chelation strategies. Thirty-three Mongolian gerbils underwent iron loading (iron dextran 500 mg/kg/wk) for 3 weeks followed by 4 weeks of chelation. An additional 56 animals received less aggressive loading (200 mg/kg/week) for 10 weeks, followed by 12 weeks of chelation. R1 and R2 calibration curves were compared to results from 23 iron-loaded animals that had not received chelation. Acute iron loading and chelation-biased R1 and R2 from the unchelated reference calibration curves but chelator-specific changes were not observed, suggesting physiologic rather than pharmacologic differences in iron distribution. Long-term chelation deferiprone treatment increased liver R1 50% (P < 0.01), while long-term deferasirox lowered liver R2 30.9% (P < 0.0001). The relationship between R1 and R2 and organ iron concentration may depend on the acuity of iron loading and unloading as well as the iron chelator administered.

Citing Articles

Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration.

Pierre T, El-Beshlawy A, Elalfy M, Al Jefri A, Al Zir K, Daar S Magn Reson Med. 2013; 71(6):2215-23.

PMID: 23821350 PMC: 4238736. DOI: 10.1002/mrm.24854.


The relationship between cardiac and liver iron evaluated by MR imaging in haematological malignancies and chronic liver disease.

Virtanen J, Remes K, Itala-Remes M, Saunavaara J, Komu M, Partanen A Blood Cancer J. 2012; 2(1):e49.

PMID: 22829233 PMC: 3270252. DOI: 10.1038/bcj.2011.48.


Magnetic resonance imaging quantification of liver iron.

Sirlin C, Reeder S Magn Reson Imaging Clin N Am. 2010; 18(3):359-81, ix.

PMID: 21094445 PMC: 3430384. DOI: 10.1016/j.mric.2010.08.014.


Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease.

Ghugre N, Gonzalez-Gomez I, Butensky E, Noetzli L, Fischer R, Williams R Am J Hematol. 2009; 84(8):480-3.

PMID: 19536851 PMC: 2884400. DOI: 10.1002/ajh.21456.


Spleen R2 and R2* in iron-overloaded patients with sickle cell disease and thalassemia major.

Brewer C, Coates T, Wood J J Magn Reson Imaging. 2009; 29(2):357-64.

PMID: 19161188 PMC: 2906451. DOI: 10.1002/jmri.21666.

References
1.
Guyader D, Gandon Y, Deugnier Y, Jouanolle H, Loreal O, Simon M . Evaluation of computed tomography in the assessment of liver iron overload. A study of 46 cases of idiopathic hemochromatosis. Gastroenterology. 1989; 97(3):737-43. DOI: 10.1016/0016-5085(89)90646-x. View

2.
Hershko C, Konijn A, Nick H, Breuer W, Cabantchik Z, Link G . ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood. 2001; 97(4):1115-22. DOI: 10.1182/blood.v97.4.1115. View

3.
Wood J, Michael Tyszka J, Carson S, Nelson M, Coates T . Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2003; 103(5):1934-6. DOI: 10.1182/blood-2003-06-1919. View

4.
Anderson L, Wonke B, Prescott E, Holden S, Walker J, Pennell D . Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002; 360(9332):516-20. DOI: 10.1016/s0140-6736(02)09740-4. View

5.
Obejero-Paz C, Yang T, Dong W, Levy M, Brittenham G, Kuryshev Y . Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy. J Lab Clin Med. 2003; 141(2):121-30. DOI: 10.1067/mlc.2003.18. View